Browsing by author "Westaby, Daniel"
Now showing items 1-9 of 9
-
Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer.
Neeb, A; Figueiredo, I; Gurel, B; Nava Rodrigues, D; Rekowski, J; et al. (ELSEVIER SCIENCE INC, 2023-08-29)BCL-2-associated athanogene-1L (BAG-1L) is a critical co-regulator that binds to and enhances the transactivation function of the androgen receptor, leading to prostate cancer development and progression. Studies investigating ... -
Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer.
Grochot, R; Carreira, S; Miranda, S; Figueiredo, I; Bertan, C; et al. (ELSEVIER, 2023-06-01)BACKGROUND: Germline mutations in the ataxia telangiectasia mutated (ATM) gene occur in 0.5-1% of the overall population and are associated with tumour predisposition. The clinical and pathological features of ATM-mutated ... -
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer.
Fenor de la Maza, MD; Chandran, K; Rekowski, J; Shui, IM; Gurel, B; et al. (ELSEVIER, 2022-04-28)BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease in which molecular stratification is needed to improve clinical outcomes. The identification of predictive biomarkers can have ... -
Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer.
Donners, R; Figueiredo, I; Westaby, D; Koh, D-M; Tunariu, N; et al. (BMC, 2023-12-15)BACKGROUND: Bone biopsies in metastatic castrate-resistant prostate cancer (mCRPC) patients can be challenging. This study's objective was to prospectively validate a multiparametric bone MRI (mpBMRI) algorithm to facilitate ... -
Optimising CT-guided biopsies of sclerotic bone lesions in cancer patients.
Donners, R; Fotiadis, N; Figueiredo, I; Blackledge, M; Westaby, D; et al. (SPRINGER, 2022-07-26)OBJECTIVES: Investigate the laboratory, imaging and procedural factors that are associated with a tumour-positive and/or NGS-feasible CT-guided sclerotic bone lesion biopsy result in cancer patients. METHODS: In total, 113 ... -
RNASEH2B loss and PARP inhibition in advanced prostate cancer.
Carmichael, J; Figueiredo, I; Gurel, B; Beije, N; Yuan, W; et al. (American Society for Clinical Investigation, 2024-06-04)BACKGROUND: Clinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). RNASEH2B loss is unrelated to HRD and preclinically sensitizes to PARP inhibition. The ... -
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Guo, C; Sharp, A; Gurel, B; Crespo, M; Figueiredo, I; et al. (NATURE PORTFOLIO, 2023-11-30)Inflammation is a hallmark of cancer1. In patients with cancer, peripheral blood myeloid expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter survival and treatment resistance across ... -
Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer.
Westaby, D; Jimenez-Vacas, JM; Padilha, A; Varkaris, A; Balk, SP; et al. (MDPI, 2021-12-23)Despite major improvements in the management of advanced prostate cancer over the last 20 years, the disease remains invariably fatal, and new effective therapies are required. The development of novel hormonal agents and ... -
Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.
Scott, E; Hodgson, K; Calle, B; Turner, H; Cheung, K; et al. (SPRINGERNATURE, 2023-03-16)Prostate cancer is the most common cancer in men and it is estimated that over 350,000 men worldwide die of prostate cancer every year. There remains an unmet clinical need to improve how clinically significant prostate ...